Mitumomab ?
Monoclonal antibody
Type Whole antibody
Source Mouse
Target GD3 ganglioside
Clinical data
Pregnancy cat.  ?
Legal status  ?
CAS number 216503-58-1 N
ATC code None
KEGG D05061 YesY
Chemical data
Formula  ?
 N(what is this?)  (verify)

Mitumomab (BEC-2) is a mouse monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. As of September 2009, the drug is undergoing Phase III clinical trials.[1][2]

See also